MedTrace Logo

A Human Trial to Evaluate the Efficacy and Safety of Fermented Turmeric in Subjects Showing Mild Hepatic Injury

NCT01634256 · Status: COMPLETED · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2012-10-04

Study results available
· View outcomes & findings →

Summary

The investigators performed a double-blind parallel study in a group of showing mild hepatic injury subjects who were given Fermented turmeric over a period of 12 weeks. The investigators measured liver function parameters , including ALT(Alanine Transaminase), AST(Aspartate Transaminase), ALP(Alkaline Phosphatase), γ-GT(Gamma-Glutamyl Transferase), and serum bilirubin, and monitored their blood pressure.

Conditions

  • Mild Hepatic Injury

Interventions

DIETARY_SUPPLEMENT

Placebo

Placebo(3.0g/day)

DIETARY_SUPPLEMENT

Fermented turmeric

Fermented turmeric(3.0g/day)

Sponsors & Collaborators

  • Chonbuk National University Hospital

    lead OTHER

Principal Investigators

  • Sang-Wook Kim, MS · Chonbuk National University Hospital

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
19 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2011-02-28
Primary Completion
2011-10-31
Completion
2012-01-31

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01634256 on ClinicalTrials.gov